ライフサイエンスコーパス: hypokalemia

1 laboratory monitoring AEs (hyperkalemia and hypokalemia).

2 er blood volume and pressure without causing hypokalemia.

3 tion, or--less frequently--hypertension with hypokalemia.

4 ium deficiency is frequently associated with hypokalemia.

5 y alone, however, does not necessarily cause hypokalemia.

6 truction, complicated by severe diarrhea and hypokalemia.

7 irst course of therapy, and in patients with hypokalemia.

8 tassium gradient was high in the presence of hypokalemia.

9 duct mediates K+ conservation during chronic hypokalemia.

10 ity characterized by hypophosphatemia and/or hypokalemia.

11 fter presenting with metabolic alkalosis and hypokalemia.

12 easing K+ transport from blood to CSF during hypokalemia.

13 ut was associated with an increased risk for hypokalemia.

14 ing, fatigue, hypersensitivity reaction, and hypokalemia.

15 d risk of hyperkalemia and a reduced risk of hypokalemia.

16 resis as well as renal potassium wasting and hypokalemia.

17 locorticoid receptor, which is enhanced with hypokalemia.

18 erum potassium levels and a low incidence of hypokalemia.

19 od was applied to predict the development of hypokalemia.

20 tical role in human ectopic heartbeats under hypokalemia.

21 is activated by low potassium intake and by hypokalemia.

22 E has an important role in the prevention of hypokalemia.

23 pplied to monitor patients at risk for hyper/hypokalemia.

24 ther away from the INa threshold, such as in hypokalemia.

25 , vs. 9.1% in the placebo group) but reduced hypokalemia.

26 human urine, the latter being diagnostic for hypokalemia.

27 e of electrolyte abnormalities, particularly hypokalemia.

28 atch-clamped ventricular myocytes exposed to hypokalemia (1.0-3.5 mmol/L) in the absence or presence

29 tion impairment (14.9%; 95% CI, 6.2%-28.3%), hypokalemia (11.9%; 95% CI, 3.9%-25.6%), hearing loss (1

30 a (29.0% v 34.5%), diarrhea (11.2% v 19.6%), hypokalemia (13.1% v 14.9%), anemia (13.9% v 13.6%), thr

31 reported adverse events were pyrexia (18%), hypokalemia (15%), and hypophosphatemia (15%).

32 nt-resistant hypertension, 6351 (43.5%) with hypokalemia, 1537 (10.5%) younger than 35 years, and 445

33 re anemia (36%), thrombocytopenia (21%), and hypokalemia (17%).

34 brile neutropenia (47% v 35%, respectively), hypokalemia (18% v 11%, respectively), thrombocytopenia

35 In intact hearts, moderate hypokalemia (2.7 mmol/L) significantly increased tissue

36 verload with BayK8644, and ionic stress with hypokalemia; 2), computer simulations using a physiologi

37 22% in arms A, B, and C, respectively), and hypokalemia (21%, 15%, and 5% in arms A, B, and C, respe

38 The most common toxicities were hypokalemia (22 caspofungin vs 13 fluconazole), respirat

39 nd sustained vasodilation vs usual care were hypokalemia (23% vs 25%), worsening renal function (21%

40 was a high lactate level (48%), followed by hypokalemia (27.4%); 59 (58.2%) patients had hyperglycem

41 a (5.0% v 14.4%), stomatitis (1.3% v 13.6%), hypokalemia (3.6% v 10.8%), and treatment-related deaths

42 itis, palmar-plantar erythrodysesthesia, and hypokalemia (400 mg twice per day; n = 1); and grade 3 t

43 re anemia (64.8%), thrombocytopenia (62.0%), hypokalemia (49.3%), neutropenia (47.9%), and peripheral

44 5%), elevated conjugated bilirubin (5%), and hypokalemia (5%).

45 In children with leukemia, grade 4 hypokalemia (50 mg/m(2)), grade 3 diarrhea (85 mg/m(2)),

46 patients), nausea (74.5%), vomiting (52.7%), hypokalemia (50.9%), and febrile neutropenia (45.5%).

47 Hypokalemia (6 cases in patients receiving vemurafenib a

48 Grade>=3 AE included neutropenia (28%), hypokalemia (8%), seizure (8%), thromboembolic event (8%

49 or 2; the most frequent grade >/= 3 AEs were hypokalemia (8.9%), thrombocytopenia (8.0%), and fatigue

50 intravenous furosemide increases the risk of hypokalemia a especially when baseline K(+) is <=4.3 mmo

51 opic drugs are administered to patients with hypokalemia, abnormal T wave morphology, HCV infection,

52 stinal peptideoma [VIPoma], watery diarrhea, hypokalemia-achlorhydria [WDHA], glucagonoma [glucagonom

53 RG) Our results show that chronic hypoxia or hypokalemia additively reduced I(hERG) with fentanyl.

54 one were more likely to be hospitalized with hypokalemia (adjusted hazard ratio, 3.06 [CI, 2.04 to 4.

55 r more current antihypertensive medications; hypokalemia; age younger than 35 years; or adrenal nodul

56 Hypokalemia also leads to worse outcomes in patients wit

57 imbalances, such as reduced serum K+ levels (hypokalemia), also trigger these potentially fatal arrhy

58 as no association between the development of hypokalemia and 30- and 90-day mortality and readmission

59 ential therapeutics for conditions involving hypokalemia and acid-base abnormalities.

60 y, one must consider CF when confronted with hypokalemia and alkalosis in a previously healthy patien

61 sade de pointes often occurs with underlying hypokalemia and bradycardia.

62 mg/m2, including nausea, vomiting, diarrhea, hypokalemia and cardiovascular problems.

63 K current suppression by hypokalemia and dofetilide alone in the absence of CaMKI

64 treatment-emergent adverse events, including hypokalemia and elevated serum aminotransferases, were m

65 Hypokalemia and even low-normal plasma potassium levels

66 riables associated with risk of TdP included hypokalemia and female gender; by contrast, persistent a

67 sy-to-implement strategies to deal with both hypokalemia and hyperkalemia are provided as well as gui

68 Although the extremes of hypokalemia and hyperkalemia at 4 weeks were associated

69 Dyskalemia (i.e., hypokalemia and hyperkalemia) in heart failure is common

70 Likewise, the adjusted hazard ratios for hypokalemia and hyperkalemia, normokalemia as reference,

71 des of treatment failures, and incidences of hypokalemia and hypoglycemia.

72 iarrhea and vomiting with concurrent grade 3 hypokalemia and hyponatremia.

73 ats and sudden death of transgenic mice with hypokalemia and imply that K2P1 leak cation channels may

74 e of spironolactone was associated with less hypokalemia and improved survival in patients with sever

75 rption in outer medullary collecting duct in hypokalemia and in acid-base regulation in conditions th

76 between pre-cardiac arrest hyperkalemia and hypokalemia and in-hospital cardiac arrest and outcomes

77 on-dose-limiting grade 3 toxicities included hypokalemia and lymphopenia.

78 Key secondary outcomes were the incidence of hypokalemia and potassium reduction stratified by baseli

79 Concomitant magnesium deficiency aggravates hypokalemia and renders it refractory to treatment by po

80 enabled by membrane hyperpolarization during hypokalemia and short action potential configurations.

81 There was no clear association between hypokalemia and these outcomes.

82 ides a mechanism to explain the link between hypokalemia and torsade de pointes.

83 Long-term toxicities occurred in 2 patients: hypokalemia and tremor, both grade III, on days 370 and

84 ut (Nedd4L(Pax8/LC1) ) mice exhibited severe hypokalemia and urinary K(+) wasting.

85 were the proportion of children with severe hypokalemia and weight change.

86 Of these, 12,787 (4.0%) represented hypokalemia, and 15,842 (5.0%) represented hyperkalemia;

87 Additionally, chronic hypoxia, hypokalemia, and alkalosis can increase the block of hER

88 genetic condition characterized by polyuria, hypokalemia, and alkalosis.

89 e, night sweats, diarrhea, nausea, vomiting, hypokalemia, and cough.

90 mice demonstrated severe metabolic acidosis, hypokalemia, and early nephrocalcinosis.

91 rticoid receptors, causing sodium retention, hypokalemia, and hypertension.

92 ell as nephrotoxicity with secondary anemia, hypokalemia, and hypomagnesemia.

93 evaluate the incidence and risk factors for hypokalemia, and its impact on mortality and readmission

94 ing duct of mouse kidney caused hypotension, hypokalemia, and metabolic alkalosis, an exact mirror im

95 pe, characterized by renal salt loss, marked hypokalemia, and metabolic alkalosis.

96 of NaCl, K+, and water, causing hypovolemia, hypokalemia, and polyuria.

97 A combination of bradycardic stimulation, hypokalemia, and quinidine resulted in early afterdepola

98 group (abdominal pain, diarrhoea, dyspnoea, hypokalemia, and respiratory failure), and four (15%) pa

99 of abnormal liver function tests, diarrhea, hypokalemia, and thrombocytopenia.

100 characterized by acute attacks of weakness, hypokalemia, and thyrotoxicosis of various etiologies.

101 to 0.84) but was not associated with risk of hypokalemia (aOR, 1.01; 95% CI, 0.95 to 1.07).

102 th a higher risk of an eating disorder were: hypokalemia (aOR, 1.98; 95% CI, 1.70-2.32), hyperkalemia

103 Hyperkalemia and hypokalemia are common in admitted patients and recogniz

104 potassium levels and minimizing the risk of hypokalemia associated with other potassium control meas

105 exhibited early afterdepolarizations during hypokalemia, associated with Ca(2+) overload.

106 ding KD diet to rats resulted in significant hypokalemia at 14 d but not at 6 d.

107 -limiting neutropenia, thrombocytopenia, and hypokalemia at 300 mg/m(2)/d.

108 everity was associated with injury severity, hypokalemia, baseline CIWA-Ar score, and established alc

109 pendently associated with the development of hypokalemia: baseline K(+) values (OR per 0.1 units, 0.8

110 electrolyte abnormalities (eg, hyponatremia, hypokalemia), bradycardia, disturbances in reproductive

111 respectively), rash, fatigue, anorexia, and hypokalemia, but not more late toxicity.

112 nnels contribute to ectopic heartbeats under hypokalemia, by analysis of transgenic mice, which condi

113 Hypokalemia causes ectopic heartbeats, but the mechanism

114 y significant arrhythmias, and post-dialysis hypokalemia compared with hemodialysate potassium 2.0/no

115 se was also associated with a higher risk of hypokalemia compared with hydrochlorothiazide use, which

116 of eGFR decline, cardiovascular events, and hypokalemia compared with hydrochlorothiazide use.

117 n isolated rat myocytes exposed to simulated hypokalemia conditions (reduction of extracellular [K(+)

118 d endocytic degradation under low potassium (hypokalemia) conditions.

119 s associated with secondary hypertension and hypokalemia, consistent with pseudohyperaldosteronism, a

120 d creatinine, or hyperkalemia (increased) or hypokalemia (decreased) related to finerenone did not di

121 constipation, febrile neutropenia, fatigue, hypokalemia, decreased appetite, and decreased white blo

122 Hypokalemia developed in 5/51 (10%) and 6/56 patients (1

123 Hypokalemia developed in 57 patients (19%) and hypernatr

124 less than 3.1 mEq/L and hospitalization for hypokalemia differed among those with and without prior

125 on is more effective in normokalemia than in hypokalemia due to the difference in dynamical threshold

126 isodic flaccid paralysis of muscle and acute hypokalemia during attacks.

127 nism in which NEDD4-2 deficiency exacerbates hypokalemia during dietary K(+) restriction primarily th

128 ill within the normal range and before frank hypokalemia ensues, in addition to the classic feedback

129 is dynamical threshold becomes much lower in hypokalemia, especially with respect to calcium, as pred

130 They found that hypokalemia evoked HERG channel ubiquitination, enhanced

131 nism, limitation of diuretics, correction of hypokalemia, exercise, and diet.

132 Ventricular cells subjected to hypokalemia exhibited Ca(2+) overload and increased gene

133 341 included thrombocytopenia, hyponatremia, hypokalemia, fatigue, and malaise.

134 mer were more likely to be hospitalized with hypokalemia for all 6 comparisons in which a statistical

135 istically significant increased incidence of hypokalemia for chlorthalidone vs hydrochlorothiazide wa

136 de a strong diuretic regimen without causing hypokalemia for patients with fluid overload, including

137 Hypokalemia, gout, new-onset diabetes mellitus, skin all

138 Hypertension (grade 3, 12%) and hypokalemia (grade 3, 6%; grade 4, 3%) were the most fre

139 After adjustment for hypokalemia, HCV infection, HIV infection, and abnormal

140 g QT had significantly higher frequencies of hypokalemia, hepatitis C virus (HCV) infection, HIV infe

141 as abnormal test results for a composite of hypokalemia, hyperkalemia, hyponatremia, hypernatremia,

142 Patients with hypokalemia, hypermagnesemia, or postcardiac surgery atr

143 ded diarrhea, hypoalbuminemia, hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia; 14 patien

144 gation were female sex, QT-prolonging drugs, hypokalemia, hypocalcemia, hyperglycemia, high creatinin

145 f infusion-related reactions, renal failure, hypokalemia, hypomagnesemia, and anemia than patients in

146 ltiple time-points, and frequency of anemia, hypokalemia, hypomagnesemia, and liver toxicity were sim

147 The incidence of worsening kidney function, hypokalemia, hypotension, and adverse events was similar

148 and female survivors are fertile but exhibit hypokalemia, hypotonic polyuria, and apparent mineraloco

149 a resolution, at the risk of inducing severe hypokalemia in addition to hyponatremia, hypotension, an

150 annel aquaporin 2, and improved polyuria and hypokalemia in mutant mice.

151 nd K(+) balance and promotes hypotension and hypokalemia in response to Na(+) and K(+) depletion, res

152 /pendrin system may explain thiazide-induced hypokalemia in some patients.

153 d by various factors such as hyperkalemia or hypokalemia in the long term, or by delayed afterdepolar

154 oms or syndromes, including hypertension and hypokalemia (in patients with aldosteronoma), Cushing sy

155 ificant electrolyte disorders, mostly due to hypokalemia, in acutely ill children compared with previ

156 Distinct mechanisms underlie hypokalemia-induced arrhythmia in the ventricle and atri

157 tifying unbridled turnover as a mechanism of hypokalemia-induced arrhythmia.

158 n diuretics are used; and (3) concerns about hypokalemia-induced arrhythmias have been overstated.

159 differential diagnosis of corticosteroid or hypokalemia-induced myopathy in Crohn's disease.

160 notably including AQP2, is an early event in hypokalemia-induced NDI.

161 tion of Kir2.6 predisposes the sarcolemma to hypokalemia-induced paradoxical depolarization during at

162 inactive analogue KN-92, abolished EADs and hypokalemia-induced ventricular tachycardia/fibrillation

163 Hypokalemia is associated with excess morbidity and mort

164 Chronic hypokalemia is known to induce renal structural and func

165 Hypokalemia is known to promote ventricular arrhythmias,

166 Hypokalemia is not addressed here.

167 hen HCTZ is added to furosemide, the risk of hypokalemia is present with higher baseline K(+) values

168 Severe hyperkalemia (K + > 6.5) and hypokalemia (K + < 2.5) were associated with 2.03 (95% C

169 =6.0 mEq/L, and a 4.7% absolute decrease in hypokalemia (K(+) <3.5 mEq/L).

170 ence and risk factors for the development of hypokalemia (K(+) <3.5 mmol/L) and its association with

171 d serum K(+) concentrations that occur under hypokalemia, K2P1 two-pore domain K(+) channels change i

172 significant electrolyte disorder, defined as hypokalemia less than 3.5 mmol/L, hypernatremia greater

173 Hypokalemia (low serum potassium level) is a common elec

174 LDO/salt + furosemide and was accompanied by hypokalemia (<3.4 mmol/l) that were rescued by spironola

175 t common gastrointestinal adverse event, and hypokalemia (<3.5 mEq/L) occurred in 5.6% of patients.

176 /L with escalating doses, and no episodes of hypokalemia (<3.5 mEq/L) were observed.

177 Hypokalemia (<3.5 mEq/L), normokalemia (3.5-5.0 mEq/L),

178 However, these hypokalemia-mediated changes occur in a handful of condi

179 ive haemorrhage in basal ganglia and chronic hypokalemia-mediated nephrocalcinosis and renal cysts.

180 ntal retardation, and electrolyte imbalance (hypokalemia, metabolic alkalosis, and hypomagnesemia).

181 autoimmune thrombocytopenia (n = 1; 2%), and hypokalemia (n = 1; 2%), which resolved spontaneously or

182 entified: heart failure (n=8), angina (n=2), hypokalemia (n=1), adverse antiarrhythmic drug treatment

183 ypercalcemia at 15 mg/m(2); hypophosphatemia/hypokalemia, neutropenia, and somnolence at 40 mg/m(2);

184 Transient elevation of liver enzymes and hypokalemia occurred frequently.

185 mmon adverse event (in 11% of the patients); hypokalemia occurred in 3%.

186 % (SZC) and 37.6% (placebo) of participants; hypokalemia occurred in 3.0% (SZC) and 1.4% (placebo).

187 In part B (n = 12), 1 DLT (grade 3 hypokalemia) occurred during course 1, and 3 of 11 patie

188 Hypokalemia occurs in up to 20% of hospitalized patients

189 from direct and perhaps distinct effects of hypokalemia on cardiomyocytes.

190 afety outcomes included hospitalization with hypokalemia or hyponatremia.

191 f SLC26A7 in states that are associated with hypokalemia or increased medullary tonicity.

192 rate or blood pressure, nor did it result in hypokalemia or worsening renal function.

193 ated by certain conditions, such as hypoxia, hypokalemia, or alkalosis, which may increase the risk o

194 alance, low blood pressure, vasopressor use, hypokalemia, or hypophosphatemia.

195 ributing factors, such as drugs that promote hypokalemia; or using an alternative therapy.

196 e that Na-K pump inhibition by even moderate hypokalemia plays a critical role in promoting EAD-media

197 se to hyperkalemia, whereas values >2 during hypokalemia point to renal loss.

198 f hyperkalemia (potassium >/=5.5 mmol/L) and hypokalemia (potassium <3.5 mmol/L) and the relationship

199 utcomes included achieved blood pressure and hypokalemia (potassium level <3.1 mEq/L; to convert to m

200 tted to the study on the basis of documented hypokalemia (potassium of < 3.5 mmol/L) within the 24-hr

201 us 4.2%; P<0.046), as well as lower rates of hypokalemia (potassium<3.5 mmol/L; 5.6% versus 17.9%; P<

202 laxative use with risk of dyskalemia (i.e., hypokalemia [potassium <3.5 mEq/L] or hyperkalemia [>5.5

203 h severe hypoglycemia; 2) with limitation of hypokalemia, potassium supplementation could limit hypog

204 6045 [3.4%] [P < .001]; hospitalization for hypokalemia: prior MI or stroke, 14 of 733 [1.9%] vs 16

205 This observation provides insight into why hypokalemia promotes calcium-mediated triggered activity

206 thy, tremor, constipation, dyspnea, hypoxia, hypokalemia, rash, and edema.

207 relative to the severity of hyperkalemia and hypokalemia remains uncertain.

208 Hypokalemia, reversible increases in serum creatinine le

209 encodes K(ir)5.1, may have tubulopathy with hypokalemia, salt wasting, and hearing loss.

210 tubulopathy characterized by hypomagnesemia, hypokalemia, salt wasting, and nephrocalcinosis, we iden

211 Hypokalemia seen with heat stress is secondary to sweat

212 id-suppressible hyperaldosteronism may cause hypokalemia, suppressed plasma renin activity, and hyper

213 served that the stimulus needed was lower in hypokalemia than in normokalemia in both computer simula

214 ver, the mechanism of renal K(+) wasting and hypokalemia that develop in individuals with ROMK Bartte

215 ctors were simultaneously present, including hypokalemia that was the most common (52%).

216 ngly with the severity of DKA, the degree of hypokalemia, the presence of complications, and admissio

217 y NaCl wasting, and metabolic alkalosis with hypokalemia, thereby recapitulating the phenotype of Bar

218 e of the patients reported CTC grades 3 to 4 hypokalemia, three reported CTC grade 3 acute renal inju

219 exposed to either oxidative stress (H2O2) or hypokalemia to induce bradycardia-dependent EADs at a lo

220 A patient with hypertension and hypokalemia underwent an adrenal venous effluent samplin

221 placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and

222 Hypokalemia was associated with an increased risk of in-

223 um tremens (odds ratio, 6.08; p = 0.01), and hypokalemia was borderline significant (odds ratio, 3.23

224 The incidence of hypokalemia was higher in the chlorthalidone group than

225 Hypokalemia was less frequent (33 vs. 58 patients) with

226 doubling of creatinine were more likely and hypokalemia was less likely in patients receiving spiron

227 Hypokalemia was noted in 2 encounters (0.2%) at 24 hours

228 Ca(2+)-dependent spontaneous activity during hypokalemia was only observed in a minority of atrial ce

229 Hypokalemia was resolved in all patients (2.6 mmol/L +/-

230 Hypokalemia was seen in 12 children (48%) receiving the

231 The incidence of hypokalemia was significantly higher in the HCTZ group (

232 s assigned to 32 degrees C, the incidence of hypokalemia was similar in both groups.

233 dence of hospitalization for hyperkalemia or hypokalemia was similar in the two groups.

234 orticoid-related toxicities (hypertension or hypokalemia) was reduced by adding low-dose prednisone.

235 Hypomagnesemia, hypocalcemia, and hypokalemia were not found.

236 ytopenia, abnormal liver function tests, and hypokalemia were reported more often for SRL-ST therapy.

237 reactions (mainly hypotension, flushing, and hypokalemia) were self-limiting and not higher than grad

238 including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abirat

239 eated with furosemide alone a higher risk of hypokalemia when baseline K(+) values are <=3.7 mmol/L.

240 Hypokalemia, which causes only intracellular acidosis, c

241 Hypokalemia, which frequently occurs among dialysis pati

242 ial depolarization, hearts were subjected to hypokalemia, which had no effect in wild-type hearts but

243 nal failure, and metabolic alkalosis without hypokalemia, which were all corrected with salt replacem

244 The excess risk of hypokalemia with chlorthalidone was attenuated in partic

245 the kidney, but is most likely secondary to hypokalemia with ECF volume contraction.

246 elman-like syndrome (fortuitous discovery of hypokalemia with hypomagnesemia and/or hypocalciuria in

247 lt to control the patient's hypertension and hypokalemia with medical therapy alone.

248 with HF exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs an

249 ter modeling revealed that EAD generation by hypokalemia (with or without dofetilide) required Na-K p